T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive malignancy in which multiple genetic defects collaborate in the transformation of T-cell progenitors[@R4],[@R5]. Notably, T-ALL has a 3-fold higher incidence in males[@R3], while other immature hematologic tumors such as precursor B-lineage ALL (BCP-B-ALL) are equally frequent in males and females[@R3].

To identify a possible X-linked tumor suppressor in T-ALL, we performed an X chromosome targeted mutation analysis in tumor DNA samples from 12 male T-ALL cases. For each sample, we performed in-solution DNA capture of 7,674 regions encompassing 3,045,708 nucleotides corresponding to 5,215 X chromosome exons using the Agilent Sure Select oligonucleotide capture system[@R6]. DNA samples enriched for X chromosome exons were then analyzed by next generation sequencing using the SOLiD 3 platform. This analysis identified 66 candidate novel non-synonymous single nucleotide variants and 7 positions with high confidence calls for containing complex variants such as insertions or deletions ([Fig. 1a](#F1){ref-type="fig"}). Dideoxynucleotide DNA sequencing of PCR products encompassing affected exons confirmed the presence of 61/66 (92%) of these single nucleotide variants and 4/7 (57%) of the more complex variants, including 2 insertions and 2 deletions ([Supplementary Tables 1 and 2](#SD1){ref-type="supplementary-material"}). Sequence analysis of paired DNA samples obtained at the time of clinical remission showed that most of these variants corresponded to previously unreported germline polymorphisms. However, and most notably, we also identified three somatically acquired changes corresponding to two non-synonymous single nucleotide substitutions (c.902A\>G, p.T300A and c.990A\>G, p.H330R) and a frameshift-creating insertion of 5 nucleotides (c.124_125insAGGCA, p.H43fs) in the *PHF6* (plant homeodomain finger 6) gene ([Fig. 1a](#F1){ref-type="fig"}).

In a complementary approach, we analyzed X chromosome array comparative genome hybridization (array-CGH) data from 246 primary T-ALL samples (179 male and 67 female) in a multi-centre setting. These analyses revealed the presence of recurrent deletions in chromosomal band Xq26 in 8 out of 246 (∼3%) T-ALL samples ([Table 1](#T1){ref-type="table"}). For 3 del(X)(q26) positive T-ALL cases, we performed array-CGH analysis against the corresponding remission material, which showed that these Xq26 deletions are somatically acquired leukemia-associated genetic events ([Table 1](#T1){ref-type="table"}). Re-analysis of all 8 del(X)(q26) positive T-ALL cases on a custom high-resolution chromosome X oligonucleotide array ([Fig. 1b,c](#F1){ref-type="fig"}) narrowed down the common minimally deleted region to an area of 80 kb containing the *PHF6* gene. Consistently, quantitative PCR analysis confirmed loss of the *PHF6* locus in the del(X)(q26) positive cases ([Fig. 1d](#F1){ref-type="fig"}). The convergent findings of our X chromosome exon mutation analysis and analysis of copy number alterations by array-CGH thus identified the *PHF6* gene as a new tumor suppressor mutated and deleted in T-ALL.

*PHF6* encodes a plant homeodomain (PHD) factor containing four nuclear localization signals and two imperfect PHD zinc finger domains[@R7] with a proposed role in the control of gene expression[@R7]. Notably, inactivating mutations in *PHF6* cause the Börjeson-Forssman-Lehmann syndrome (BFLS; MIM\#301900), a relatively uncommon type of X-linked familial syndromic mental retardation which has not been associated with increased incidence of T-ALL[@R7]-[@R9]. Quantitative RT-PCR analysis demonstrated ubiquitous expression of *PHF6* transcripts in human tissues, with the highest levels of expression in thymus, ovary and thyroid and moderate levels of expression in spleen, testes and adipose tissue ([Supplementary Fig. 1](#SD1){ref-type="supplementary-material"}). Consistent with these results, PHF6 was readily detected by immunohistochemistry in mouse thymus ([Supplementary Fig. 1](#SD1){ref-type="supplementary-material"}). Finally, quantitative RT-PCR analysis of human thymocyte populations at different stages of development showed variable levels of *PHF6* expression, with marked upregulation of *PHF6* transcripts in CD4/CD8 double positive cells ([Supplementary Fig. 1](#SD1){ref-type="supplementary-material"}).

Mutation analysis of *PHF6* in an extended panel of pediatric and adult T-ALL primary samples identified truncating or missense mutations in *PHF6* in 38% (16/42) of adult and ∼16% (14/89) of pediatric T-ALL samples ([Fig. 2a](#F2){ref-type="fig"} and [Table 1](#T1){ref-type="table"}). In all available cases (7/30), analysis of matched buccal and/or bone marrow remission genomic DNA confirmed the somatic origin of *PHF6* mutations (4/21 frameshift mutations and 3/9 missense mutations) ([Fig. 2b](#F2){ref-type="fig"} and [Table 1](#T1){ref-type="table"}). Finally, no mutations in *PHF6* were identified in DNA samples from BCP-B-ALLs (*n* = 62), suggesting that mutational loss of *PHF6* in lymphoid tumors could be restricted to T-ALL.

Nonsense and frame-shift mutations accounted for 70% (21/30) of all *PHF6* mutations identified in our series and were evenly distributed throughout the gene. Missense mutations accounted for the remaining 30% (9/30) of *PHF6* lesions and recurrently involved codon C215 and the second zinc finger domain of the protein ([Fig. 2a](#F2){ref-type="fig"}). DNA sequence analysis of *PHF6* in a panel of 15 well characterized T-ALL cell lines ([Supplementary Table 3](#SD1){ref-type="supplementary-material"}) showed the presence of truncating mutations in the *PHF6* gene in the DND41, HPB-ALL and T-ALL1 cell lines. Western blot analysis and immunohistochemical staining of PHF6 demonstrated robust expression and nuclear localization of PHF6 in *PHF6*-wild-type tumors and complete loss of PHF6 protein in T-ALL cell lines harboring mutations in *PHF6* ([Fig. 2c,d](#F2){ref-type="fig"}).

PHD finger-containing proteins have been implicated in numerous cellular functions, including transcriptional regulation and in some instances as specialized reader modules that recognize the methylation status of histone lysine residues[@R10]. In addition, PHF6 has been reported to be phosphorylated during mitosis[@R11] and by the ATM and ATR kinases upon DNA damage[@R12], which suggests a dynamic regulation of PHF6 during cell cycle and DNA repair. Consistent with this notion, shRNA knockdown of PHF6 resulted in increased levels of phosphorylated H2AX (gamma-H2AX), a posttranslational modification associated with the presence of DNA double strand breaks[@R13] ([Fig. 2e](#F2){ref-type="fig"}).

Sex determination in humans is controlled by differential representation of the X and Y chromosomes, with presence of an XY pair in the male genome and two copies of chromosome X in females. The presence of numerous genes in the non-autosomal region of the X chromosome could result in a genetic imbalance between male and female cells, which is compensated by random chromosomal inactivation of one copy of chromosome X in female cells[@R14]. However, allelic expression analysis has shown that some genes can escape X chromosome inactivation in certain tissues[@R1],[@R2],[@R15]. To test the possibility that *PHF6* could escape X-inactivation in T-ALL cells, we performed allelic expression analysis of a silent SNP (rs17317724) located in the 3′ untranslated region of *PHF6* in lymphoblasts from 3 informative female T-ALL cases. In each of these samples, *PHF6* was monoallelilically expressed, suggesting that biallelic expression of *PHF6* is not commonly found in T-ALL ([Fig. 3a](#F3){ref-type="fig"}). Most notably, we found that *PHF6* mutations are almost exclusively found in male T-ALL cases. *PHF6* mutations were present in 29/92 (32%) males and only in 1/39 (∼2.5%) females (P \< 0.001; [Fig. 3b](#F3){ref-type="fig"} and [Supplementary Table 4](#SD1){ref-type="supplementary-material"}). Moreover, all 8 *PHF6* deletions identified by array-CGH analysis were found in male T-ALL cases, and each of the three cell lines with mutations in *PHF6* were derived from male T-ALL cases.

Immunohistochemical analysis of PHF6 expression in wild-type primary T-ALL samples showed positive PHF6 immunostaining (*n* = 5; 3 males and 2 females), while cases with *PHF6* truncating mutations (*n* = 4) ([Fig. 3c](#F3){ref-type="fig"}) or a point mutation in C215 (p.C215F) were negative for PHF6 protein expression ([Fig. 3c](#F3){ref-type="fig"}). In contrast, primary T-ALL cells harboring a *PHF6* point mutation in the PHD2 domain (p.T300A) were positive for PHF6 protein expression ([Fig. 3c](#F3){ref-type="fig"}). Overall, these results suggest that truncating mutations and point mutations in C215 impair PHF6 expression, while amino acid substitutions in the PHD2 domain of PHF6 may selectively impair the tumor suppressor function of this protein.

Leukemic transformation of immature thymocytes is the result of a multistep process involving numerous genetic abnormalities, which can be associated with different clinical features, including age and prognosis. Notably, *PHF6* mutations were significantly more prevalent in adult (16/42; 38%) than in pediatric T-ALLs (14/89; 16%) (*P* = 0.005; [Fig. 4a](#F4){ref-type="fig"}). Detailed genetic information was available for T-ALL cases treated in DCOG clinical trials (*n* = 65) ([Supplementary Table 5](#SD1){ref-type="supplementary-material"}). In this cohort, *PHF6* mutations were significantly associated with the aberrant expression of *TLX1* and *TLX3* (*P* \< 0.005; [Fig. 4b](#F4){ref-type="fig"} and [Supplementary Table 5](#SD1){ref-type="supplementary-material"}), two related oncogenes activated by chromosomal translocations in T-ALL[@R16]-[@R18]. No significant associations were observed between *PHF6* mutations and mutations in *NOTCH1*, *FBXW7* or *PTEN* in either pediatric (*n* = 65) or adult (*n* = 34) T-ALL cohorts ([Supplementary Tables 5 and 6](#SD1){ref-type="supplementary-material"}). Overall survival in *PHF6* wild-type pediatric T-ALL cases treated on DCOG protocols[@R19] was 65% (33/51) vs. 71% (10/14) for *PHF6*-mutated cases (log-rank *P* = 0.71) ([Fig. 4c](#F4){ref-type="fig"}). Overall survival in *PHF6* wild-type adult T-ALL leukemias treated in the ECOG2993 clinical trial was 36% (7/12) vs. 58% (8/22) for *PHF6*-mutated samples (log-rank *P* = 0.24) ([Fig. 4d](#F4){ref-type="fig"}).

Overall, these results identify *PHF6* as a new X-linked tumor suppressor gene and strongly suggest a specific interaction between the oncogenic programs activated by aberrant expression of TLX transcription factors and the mutational loss of *PHF6* in the pathogenesis of T-ALL.
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![Next generation sequencing and array CGH analysis of the X chromosome identifies *PHF6* mutations in human T-ALL. (**a**) Overview of mutation screening approach of the human X chromosome exome in a panel of tumor DNA samples from 12 male T-ALL cases using oligonucleotide sequence capture and next generation sequencing with SOLiD3. After filtering and confirmation of high throughput sequencing data, analysis of corresponding remission DNA samples led to the identification of three somatically acquired changes in the *PHF6* gene. (**b**) Schematic overview of the recurrent genomic deletions involving chromosomal band Xq26.3 in 8 human T-ALL samples. Specific genes located in Xq26.3 are shown. (**c**) Detailed view of a representative oligo array-CGH plot of leukemia DNA/control DNA ratios (blue tracing) versus the dye-swap experiment (red tracing) in a patient harboring an Xq26.3 deletion. (**d**) DNA quantitative PCR analysis of *PHF6* copy number dose in female and male reference genomic DNAs and 2 primary samples from male T-ALL cases harboring Xq26.3 deletions.](nihms176587f1){#F1}

![*PHF6* mutations and expression in T-ALL lymphoblasts. (**a**) Structure of the PHF6 protein including four nuclear localization signals and two imperfect PHD zinc finger domains. Overview of all *PHF6* mutations identified in primary T-ALL samples and T-ALL cell lines. Filled circles represent nonsense and frameshift mutations, whereas missense mutations are depicted as open circles. Circles filled in gray indicate mutations identified in female T-ALL cases. (**b**) Representative DNA sequencing chromatograms of paired diagnosis and remission genomic T-ALL DNA samples showing a somatic mutation in exon 7 of *PHF6*. (**c**) Western blot analysis of T-ALL cell lines revealed complete loss of PHF6 protein expression in the *PHF6* mutated T-ALL cell lines. (**d**) PHF6 immunostaining in the Jurkat and HPB-ALL, wild-type and mutant T-ALL cell lines, respectively. (**e**) Western blot analysis of PHF6 and gamma-H2AX expression in HEK293T cells upon PHF6 shRNA knockdown. Actin levels are shown as loading control.](nihms176587f2){#F2}

![*PHF6* expression in T-ALL lymphoblasts. (**a**) Sequence analysis of paired genomic DNA and cDNA samples shows monoallelic expression of *PHF6* SNP rs17317724 in lymphoblasts from a wild-type *PHF6* female T-ALL case. (**b**) Differential distribution of *PHF6* mutations in T-ALL samples from male and female cases. (**c**) Immunohistochemical analysis of PHF6 expression in wild type and mutant T-ALL lymphoblasts.](nihms176587f3){#F3}

![Clinical and biological characteristics associated with *PHF6* mutations in T-ALL. (**a**) Frequencies of *PHF6* mutations in pediatric and adult T-ALL samples. (**b**) Differential distribution of *PHF6* mutations in *TLX1/TLX3* positive and negative T-ALL samples. (**c**) Kaplan-Meier curve of overall survival in pediatric T-ALL patients from DCOG trials ALL7, ALL8 and ALL9 with and without *PHF6* mutations. (**d**) Kaplan-Meier survival curve in adult T-ALL patients with and without mutations in *PHF6* treated in ECOG clinical trial ECOG2993.](nihms176587f4){#F4}

###### Characteristics of 38 primary T-ALL samples showing *PHF6* inactivation

       *PHF6* lesion                                                                               
  ---- ------------------ ------- ----- ---------- --------- ----- -------------------- ---------- ---------
       *PHF6* deletions                                                                            
                                                                                                   
  1    M                  Ped     77    Cortical   *TLX3*    mut   Deletion (0.55 Mb)              NA
  2    M                  Ped     46    Pre-T      *TLX3*    wt    Deletion (0.23 Mb)              NA
  3    M                  Ped     31    Pre-T      *TLX3*    NA    Deletion (1.50 Mb)              NA
  4    M                  Ped     2     Pre-T      unknown   NA    Deletion (0.27 Mb)              NA
  5    M                  Ped     NA    Cortical   *HOXA*    NA    Deletion (1.90 Mb)              Somatic
  6    M                  Ped     NA    Cortical   unknown   NA    Deletion (0.20 Mb)              Somatic
  7    M                  Ped     NA    Cortical   *TLX1*    NA    Deletion (0.08 Mb)              Somatic
  8    M                  Adult   NA    Pre-T      Unkn      NA    Deletion (0.11 Mb)              NA
                                                                                                   
       *PHF6* mutations                                                                            
                                                                                                   
  9    M                  Ped     185   Cortical   *TLX3*    wt    Nonsense             p.G122X    NA
  10   M                  Ped     417   Pre-T      *TLX3*    mut   Nonsense             p.R116X    NA
  11   F                  Ped     280   Pre-T      *TLX1*    mut   Frameshift           p.F172fs   NA
  12   M                  Ped     405   Pre-T      *TLX3*    mut   Frameshift           p.Y303fs   NA
  13   M                  Ped     159   Pre-T      *TLX1*    mut   Nonsense             p.K235X    NA
  14   M                  Ped     500   Pre-T      *TLX3*    mut   Frameshift           p.A41fs    NA
  15   M                  Ped     347   Cortical   *HOXA*    mut   Nonsense             p.K274X    NA
  16   M                  Ped     129   Cortical   unknown   mut   Frameshift           p.D333fs   NA
  17   M                  Ped     174   Cortical   *TLX3*    mut   Nonsense             p.R225X    NA
  18   M                  Ped     27    Cortical   *TLX1*    wt    Nonsense             p.R116X    NA
  19   M                  Ped     310   Cortical   *TAL1*    mut   Missense             p.C283R    NA
  20   M                  Ped     189   Cortical   *TAL1*    mut   Frameshift           p.C28fs    NA
  21   M                  Adult   170   Cortical   *TLX3*    wt    Frameshift           p.H44fs    NA
  22   M                  Adult   21    Cortical   *TLX1*    mut   Frameshift           p.H43fs    Somatic
  22   M                  Adult   21    Cortical   *TLX1*    mut   Frameshift           p.H43fs    Somatic
  23   M                  Adult   NA    Pre-T      *TLX3*    mut   Frameshift           p.T98fs    Somatic
  24   M                  Adult   14    Pre-T      *TLX3*    wt    Frameshift           p.Y105fs   NA
  25   M                  Adult   28    Mature     *TLX3*    wt    Frameshift           p.S158fs   NA
  26   M                  Adult   NA    Cortical   *TLX3*    mut   Missense             p.C215Y    NA
  27   M                  Adult   NA    Pre-T      Unkn      mut   Missense             p.C215F    NA
  28   M                  Adult   31    Cortical   Unkn      mut   Missense             p.C215Y    NA
  29   M                  Adult   NA    Mature     *TLX3*    mut   Missense             p.T300A    Somatic
  30   M                  Adult   21    Cortical   *TLX1*    wt    Missense             p.A311P    NA
  31   M                  Adult   30    Mature     Unkn      wt    Missense             p.C280Y    NA
  32   M                  Adult   23    Cortical   Unkn      wt    Missense             p.H329R    Somatic
  33   M                  Ped     NA    NA         *TAL1*    NA    Nonsense             p.R257X    Somatic
  34   M                  Ped     NA    NA         *TLX1*    NA    Frameshift           p.S191fs   Somatic
  35   M                  Adult   NA    NA         *TLX1*    NA    Missense             p.C215F    Somatic
  36   M                  Adult   NA    NA         *TLX1*    NA    Nonsense             p.Y303X    NA
  37   M                  Adult   NA    NA         Unkn      NA    Nonsense             p.R274X    NA
  38   M                  Adult   NA    NA         Unkn      NA    Frameshift           p.H135fs   NA

Ped, pediatric; NA, not available; mut, mutated; wt, wild-type.
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